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Objectives:Most reports of femoral-femoral bypass (FFB) were published before the era of endovascular intervention. This
study examines the utilization and impact of adjunctive endovascular intervention on FFB in contemporary practice.
Methods: We reviewed 253 FFB performed in 247 patients between 1984 and 2010. Primary endpoints, including graft
patency, primary-assisted patency, limb salvage, and survival, were assessed using Kaplan-Meier life-table analysis.
Univariate and multivariate analyses were performed to determine predictors of primary endpoints.
Results: The indication for FFB included claudication (27%; n  69) and critical limb ischemia (72%; n  184). Forty-eight
patients (19%) were treated urgently for acute ischemia. Mean follow-up was 5.6  5.5 years. Over the study interval,
adjunctive iliac percutaneous transluminal angioplasty (PTA)/stent placement increased significantly from 0% to
54% (P trend < .001), while the rate of axillofemoral bypass or no inflow procedure decreased from 100% to 46% (P
trend < .001). Despite increased utilization, iliac PTA/stenting was associated with decreased 5-year primary graft
patency of 44% compared with 74% for axillofemoral bypass patients and 71% in patients with no adjunctive inflow
procedure (P  .004). Patients with inflow iliac PTA/stents also had diminished 5-year assisted primary patency of 61%
compared with 85% for axillofemoral bypass patients and 87% in patients without inflow revascularization (P  .002).
Adjunctive iliac PTA/stenting did not impact limb salvage or overall survival. Five-year primary patency among
claudicants and critical leg ischemia patients was 65% and 68%, respectively.
Conclusions: The incidence of iliac PTA/stent placement in conjunction with FFB has increased significantly over time in
contemporary practice. Reliance on iliac stent placement for FFB inflow is paradoxically associated with both diminished
primary and assisted primary graft patency when compared with historical controls. These findings highlight the
importance of patient selection and inflow consideration when performing FFB. (J Vasc Surg 2012;55:739-45.)
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MFemoral-femoral bypass (FFB) remains a commonly
performed extra-anatomic revascularization option among
patients with multiple comorbidities and significant aor-
toiliac occlusive disease. Historically, FFB has been reliably
used for a myriad of indications, including critical limb
ischemia and severe lifestyle-limiting claudication in the
setting of unilateral inflow occlusive disease.1-9 More re-
cently, FFB has also been successfully incorporated into
surgical treatment paradigms for aortouniliac reconstruc-
tions in the setting of aneurysm disease.10 Historically,
aortobifemoral bypass (AFB) has served as the “gold stan-
dard” for aortoiliac revascularization, providing well-
documented patency and durability.2 Despite these results,
operative magnitude has often precluded direct anatomic
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doi:10.1016/j.jvs.2011.10.036evascularization among frail patients with multiple comor-
idities. Accordingly, this subset of patients has previously
ndergone extra-anatomic revascularization, including
FB performed either alone or as part of an axillobifemoral
ypass strategy.
Previously, FFB was performed most commonly among
edically high-risk patients unsuited for in-line anatomic re-
onstruction.11 Early reports identified significant donor iliac
tenosis as a risk factor for subsequent FFB failure.12,13 The
dvent of percutaneous endovascular therapies has expanded
he applicability of FFB to frail patients with concomitant
nflow iliac disease with the potential to treat such lesions with
ndovascular therapy at the time of bypass.14-17 Conse-
uently, this has led to a potential paradigm shift in the
perative management of such patients. Accordingly, histori-
al series on FFB are unlikely to accurately depict contempo-
ary “real-world” outcomes reflecting adjunctive endovascu-
ar intervention at the time of FFB. The purpose of this study
s to review trends and outcomes in FFB utilization in the
ontext of concomitant adjunctive inflow procedures per-
ormed at the time of surgery. In reviewing a large contempo-
ary cohort of FFB patients, we hope to define whether
djunctive inflow procedures performed at the time of FFB
ffect primary graft patency, primary-assisted patency, limb
alvage, or overall survival.
ETHODS
Subjects and database. Clinical, operative, and de-
ographic variables were collected retrospectively on 253
739
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March 2012740 Huded et alFFB performed on 247 patients between December 1984
and May 2010. Patients were treated by 12 surgeons at a
single academic medical center. All FFB performed during
the study interval were identified. FFB performed in the
context of an aortouniliac aneurysm repair were excluded
from this study. Adjunctive inflow procedures, including
axillofemoral bypass and iliac stenting, were performed at
the discretion of the attending surgeon at the time of the
FFB or within the preceding 1 day.
Outcomes and variable definitions. The endpoints
of this study were primary graft patency, assisted primary
patency, limb salvage, and survival. Primary and assisted
primary patency were assessed in the entire study cohort
(n  253). Failure of primary patency was defined as graft
excision, graft revision, or graft thrombosis confirmed by
duplex ultrasonography, angiography, or ankle-brachial in-
dexes. Failure of assisted primary patency was defined as any
intervention or reoperation to maintain graft patency fol-
lowing FFB. Limb salvage and survival were assessed in
patients with critical limb ischemia (n  184) defined as
acute-onset ischemia, rest pain, or tissue loss. Failure of
limb salvage was defined as any major amputation of either
lower extremity. Survival was assessed by review of the
medical record and the social security death database.
Statistical analysis. Comparisons among groups were
tested with the 2 test and one-way analysis of variance.
Univariate analysis was performed using the 2 test to
identify potentially relevant variables predictive of the main
outcome measures. Variables with a significant association
at P  .10 were used to construct a multivariate model
using backwards stepwise logistic regression. Hazard ratios
(HRs) and 95% confidence intervals (CIs) were generated
for significant endpoint predictors using Cox proportional
hazards modeling, with P  .05 considered significant.
Trends in inflow revascularization over time were analyzed
by dividing the study interval into 3-year subintervals and
applying a nonparametric test of trend. This study was
conducted in compliance with the Institutional Review
Table I. Characteristics of the study cohort overall and str
Characteristic
Overall
(n  253)
Male 143 (56%)
Age, years (range) 68 (39-96)
Diabetes 49 (20%)
Hypertension 142 (58%)
Coronary artery disease 118 (48%)
Congestive heart failure 40 (16%)
Chronic obstructive pulmonary disease 74 (30%)
Creatinine 1.8 22 (9%)
Antiplatelet 64 (39%)
Statin 13 (8%)
Antiplatelet and statin 35 (21%)
Neither antiplatelet nor statin 54 (33%)
Claudication 69 (27%)
Critical ischemia 184 (73%)
Acute ischemia 48 (19%)
Profunda outflow 78 (31%)Board at Dartmouth Medical School. nESULTS
Over the study period, 253 FFB were performed in 247
atients. Among the bypasses performed, 27% (n69)were for
ifestyle-limiting claudication, while 73% (n  184) were for
ritical limb ischemia, including 19% (n  48) that were per-
ormed emergently for acute ischemia. The use of adjunctive
nflow procedures varied among the study population. In-
ow axillofemoral bypass was performed in 34% (n  84),
hile inflow iliac stenting was performed in 16% (n  43).
wo patients underwent inflow percutaneous transluminal
ngioplasty (PTA) alone without stenting and were in-
luded in the concomitant intervention group. Nearly half
f the study population, 49% (n 125), underwent neither
nflow PTA/iliac stenting nor axillofemoral bypass at the
ime of reconstruction.
Demographics and comorbidities were typical for this
atient population, with a significant incidence of hyper-
ension, coronary artery disease, congestive heart failure,
nd diabetes. Nearly one-third of the patients had a history
f chronic obstructive pulmonary disease. Patient demo-
raphics and comorbidities varied among the three groups.
ardiac comorbidities were significantly more common in
atients undergoing adjunctive axillofemoral bypass and
ess common in patients undergoing adjunctive iliac stent-
ng. Patients undergoing axillofemoral bypass were also
ignificantly more likely to suffer from critical limb ischemia
ather than claudication. Fifty-two patients (21%) under-
ent prior inflow revascularization before ultimately un-
ergoing FFB. Of note, there was no significant difference
n profunda outflow patency status among the groups
Table I).
Trends in adjunctive inflow revascularization over
ime were evaluated, stratifying the study period into
-year intervals. Comparison of the first 3-year interval
o the most recent interval demonstrated a decrease in
he rate of inflow axillofemoral bypass grafting from 33%
o 19%. Similarly, the incidence of patients undergoing
d by inflow revascularization groups
-stented
 125)
Axillofemoral
(n  87)
Stent
(n  43) P value
(65%) 42 (48%) 21 (49%) .029
(40-96) 68 (39-86) 68 (43-93) .970
(20%) 19 (22%) 6 (14%) .525
(54%) 46 (54%) 32 (74%) .051
(48%) 48 (56%) 13 (30%) .019
(15%) 21 (25%) 1 (2%) .005
(27%) 28 (33%) 14 (33%) .622
(5%) 11 (13%) 5 (12%) .122
(45%) 16 (33%) 13 (33%) .236
(4%) 6 (12%) 4 (10%) .198
(14%) 14 (29%) 10 (25%) .125
(36%) 13 (27%) 13 (33%) .517
(36%) 7 (8%) 18 (42%) .001
(64%) 80 (92%) 25 (58%) .001
(21%) 18 (21%) 4 (9%) .206
(33%) 12 (29%) 13 (30%) .671atifie
Non
(n
80
68
24
64
57
18
32
6
35
3
11
28
44
79
26o concomitant adjunctive inflow procedure decreased
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Volume 55, Number 3 Huded et al 741from 67% to 27% over the same interval. In total, the rate
of patients who underwent either axillofemoral bypass or
no adjunctive inflow revascularization decreased from
100% to 46% (P trend  .001). Conversely, the rate of
inflow iliac stenting increased from 0% to 54% over the
study interval (P trend  .001; Fig 1).
Overall 5-year primary patency was 68%, and assisted
primary patency was 82%. There was no significant differ-
ence in patency after stratifying the cohort by surgical
indication. Primary patency was 66% among claudicants
and 69% among patients with critical limb ischemia (P 
not significant [NS]). Similarly, assisted primary patency
was 82% among both claudicants and patients with critical
limb ischemia (P  NS). Limb salvage rate at 5 years was
91%, whereas overall 5-year survival was 43% among pa-
tients with critical limb ischemia.
Univariate analysis demonstrated that adjunctive in-
flow iliac PTA/stenting was associated with diminished
primary graft patency. Five-year primary patency in pa-
tients undergoing iliac PTA/stenting was 44%, com-
pared with 74% for patients undergoing axillofemoral
bypass and 71% for patients who did not undergo ad-
junctive inflow revascularization (P  .004; Fig 2).
Additionally, assisted primary patency was diminished in
patients who underwent adjunctive inflow iliac PTA/
stenting. Five-year assisted primary patency was 61%
among adjunct iliac PTA/stent patients, compared with
85% among concomitant axillofemoral bypass, and 87%
among those without adjunctive inflow revascularization
(P  .002; Fig 3). Limb salvage rates and overall survival
did not differ among patients with limb-threatening
ischemia when stratified by adjunctive inflow revascular-
ization (Figs 4 and 5).
Multivariate logistic regression was used to control for
other variables, including medical comorbidities, adjunc-
tive medication use, remote antecedent revascularization,
and postoperative complications. Inflow iliac stenting was
identified as an independent predictor of both diminished
primary patency (HR, 2.37; CI, 1.2-4.9; P  .019) and
Fig 1. Inflow revascularization trends over the study interval.
PTA, Percutaneous transluminal angioplasty.diminished assisted primary patency (HR, 2.51; CI, 1.2- a.2; P  .013). Graft infection and previous inguinal
evascularization of the symptomatic limb were also iden-
ified as independent predictors of both diminished primary
ig 2. Primary patency stratified by adjunctive inflow revas-
ularization. PTA, Percutaneous transluminal angioplasty.
ig 3. Assisted primary patency stratified by adjunctive inflow
evascularization. PTA, Percutaneous transluminal angioplasty.
ig 4. Limb salvage stratified by adjunctive inflow revas-
ularization. PTA, Percutaneous transluminal angioplasty.nd assisted primary patency (Tables II and III).
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This study is among the first to demonstrate that the
use of adjunctive endovascular iliac PTA/stenting, per-
formed in conjunction with FFB, has significantly in-
creased in contemporary surgical practice. Paradoxically,
these endovascular interventions appear to be associated
with both diminished primary and assisted primary graft
patency. In fact, over half of all FFB procedures in recent
years were performed in conjunction with concomitant
iliac stent placement. These findings document a poten-
tially significant shift in the utilization of adjunctive
inflow procedures performed in conjunction with FFB.
Given the pervasive need for adjunctive inflow revascu-
Fig 5. Survival stratified by adjunctive inflow revascularization.
PTA, Percutaneous transluminal angioplasty.
Table II. Significant independent predictors associated
with primary patency
Hazard
ratio
95% Confidence
interval for hazard
ratio
P
valueLower Upper
Prior inflow
procedure 2.70 1.31 5.58 .007
Graft infection 3.12 1.09 8.98 .035
Inflow stent 1.09 0.97 4.04 .06
Table III. Significant independent predictors associated
with primary assisted patency
Hazard
ratio
95% Confidence
interval for hazard
ratio
P
valueLower Upper
Prior inflow
procedure 2.02 1.08 3.77 .028
Graft infection 3.92 1.44 10.68 .008
Inflow stent 2.31 1.12 4.75 .023larization at the time of FFB, these findings should have Fmportant implications when considering vascular recon-
truction among such typically debilitated patients, and
ore importantly, may have implications on midterm
raft performance.
Historically, AFB has been the “gold standard” in-
ine anatomic vascular reconstruction for patients with
nilateral or bilateral significant aortoiliac occlusive dis-
ase.2 Despite promising results, the impact of a large
ransabdominal operation and ensuing postoperative
ourse has rendered it unsuited for a growing subset of
rail patients with multiple comorbidities. Accordingly,
FB, either alone or performed as part of an axillob-
femoral extra-anatomic reconstruction, has been well
uited for such clinical circumstances. Although long-
erm results have not equaled AFB, FFB has been shown
o provide satisfactory patency and limb salvage among
uch high-risk patients with limited life expectancy.4 The
dvent of endovascular therapies for the treatment of
rterial occlusive disease has expanded the anatomic
rofile of patients deemed suitable to undergo FFB.
onsequently, patients with donor inflow disease are
natomically eligible for concomitant endovascular in-
ervention at the time of surgery, obviating the need for
more extensive extra-anatomic revascularization such
s axillobifemoral bypass. Despite this evolution in prac-
ice, reports of outcomes for FFB performed in conjunc-
ion with ipsilateral percutaneous intervention remain
omewhat limited.
Prior reports have demonstrated mixed results using
onor iliac intervention in conjunction with FFB for pa-
ients with bilateral aortoiliac occlusive disease. Lopez-
alarza et al documented associated 5-year primary pa-
ency to be 51% in a review of 18 patients who underwent
FBwith adjunctive iliac stenting in the setting of a stenosis
horter than 3 cm.15 However, these conclusions remain
imited, given the study’s small sample size and lack of
omparison to a nonstented group. Perler et al reported a
atisfactory 5-year patency of 79% among 26 patients who
nderwent iliac angioplasty or stenting at the time of FFB.
nterestingly, the study also demonstrated a 5-year patency
f 59% among patients who did not undergo endovascular
ntervention, although this was not significantly different.18
n another study, AbuRahma et al reported a series of 41
atients undergoing FFB, in which 92% underwent iliac
tenting in the setting of iliac lesions 5 cm in length as
ompared with 14% who underwent associated stenting in
he setting of a lesion 5 cm in length. Perhaps not
urprisingly, 3-year primary patency was 31% in patients
ith longer segment stenoses versus 85% in those with
horter lesions.19 Indeed, these results highlight both the
ariation in utilization of concomitant iliac stenting per-
ormed at the time of FFB and the durability of such
nterventions performed at the time of extra-anatomic by-
ass.
By comparison, this study helps to clarify both the
rowing incidence and outcomes of adjunctive endovas-
ular inflow revascularization performed at the time of
FB. Most importantly, this study demonstrates a signif-
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Volume 55, Number 3 Huded et al 743icant increase in the rate of adjunctive iliac stenting over
time from 0% to 54%. Over the same interval, the inci-
dence of axillobifemoral reconstruction or no concomi-
tant inflow procedure has decreased from 100% to 46%.
This paradigm shift likely reflects the obvious appeal and
less invasive alternative of inflow stenting compared with
axillobifemoral bypass. However, this study also docu-
ments diminished 5-year primary patency (44%) and
assisted primary patency (61%) associated with adjunc-
tive iliac stenting. By comparison, axillofemoral inflow
revascularization demonstrated 5-year primary patency
of 74%, similar to those patients who did not require any
adjunctive inflow revascularization (71%). Conceivably,
these results suggest the possibility that residual iliac
disease can remain untreated, perhaps unknowingly, at
the time of FFB, especially when performed under more
urgent or emergent conditions. Rzucidlo and colleagues
have previously demonstrated that durable iliac stenting
is predicated on thorough anatomic stenting and assess-
ment for persistent pressure gradients, necessitating the
need for thorough interrogation at the time of FFB.20
Accordingly, these findings would suggest that routine
pressure gradients should be obtained to exclude the
possibility for unappreciated occlusive disease at the time
of surgery.
While adjunctive iliac PTA/stenting was associated
with diminished primary and assisted primary patency,
5-year limb salvage rates appeared unaffected by adjunc-
tive concomitant inflow revascularization. These find-
ings appear similar to several historical reports. Sch-
neider et al documented a 3-year limb salvage rate of 88%
among patients undergoing FFB, whereas Mingoli et al
demonstrated a 5-year limb salvage rate of 78% following
FFB.2,3 Interestingly, this study demonstrated that limb
salvage rates remained largely unaffected by associated
inflow revascularization performed in conjunction with
FFB (5-year limb salvage rates: iliac PTA/stent 87%,
axillofemoral bypass 91%, no concomitant inflow proce-
dure 91%, respectively; P  NS). Additional reports
documenting associated limb salvage rates stratified by
inflow revascularization remain scarce. The aforemen-
tioned study by AbuRahma et al demonstrated no signif-
icant difference in limb salvage among patients with
long-segment (5 cm) and short-segment (5 cm)
donor iliac stenosis.19 Preserved rates of limb salvage
likely reflect the complex and multifactorial etiologies
leading to major amputation. The presence of multilevel
occlusive disease would clearly impact ongoing lower
extremity arterial insufficiency irrespective of FFB pa-
tency and accordingly account for this finding.
Overall 5-year survival following FFB was 43%, con-
cordant with other previously published series.3,6 Di-
minished survival appears to be refractory in this patient
population despite the evolution in FFB therapy toward
a combined bypass and endovascular treatment posture.
This may indeed reflect the pervasive high comorbidity
profile these patients share with associated high rates of
coronary artery disease (48%; n  118) and congestive Oeart failure (16%; n  40), among others. Therefore, it
s not surprising that inflow revascularization in conjunc-
ion with FFB has not had a significant impact on mor-
ality.
This study has several intrinsic limitations. First, it
emains a single-center retrospective study. Neverthe-
ess, it does reflect the treatment utilization and overall
esults in a “real-world” academic medical center prac-
ice. Furthermore, adjunctive procedures were deter-
ined by the operating attending surgeon, and thus we
emain limited in our ability to discern differences at the
urgeon level in choosing various adjunctive procedures
ver the extended study interval. Additionally, details
urrounding the anatomic disease burden/TransAtlantic
nter-Society Consensus (TASC) classification of the
atients undergoing therapy remain limited. Although
xillofemoral bypass would intuitively be more prevalent
mong patients with more advanced occlusive disease
rofiles, this study has clearly demonstrated decreased
tilization of this procedure over time. Moreover, TASC
lassification changed over the study interval, further
onfounding any ability to classify disease severity at the
ime of surgery. Additionally, since only two patients
nderwent PTA alone, we remain more limited in our
onclusions of this small subset of patients. Accordingly,
t remains unclear whether these patients had sufficiently
ild inflow aortoiliac occlusive disease to obviate con-
omitant stent placement, in whom FFB patency was not
iminished, or whether the necessity of adjunctive inflow
ngioplasty at the time of surgery rather reflected a
emodynamically significant donor iliac stenosis, which
ay contribute to diminished long-term patency. Nev-
rtheless, these results do reflect “real-world” practice
ver time in a busy academic medical center practice.
ONCLUSIONS
This series of 253 FFB spanning the current era of
ndovascular intervention demonstrates an increase in the
ncidence of adjunctive iliac stenting at the time of FFB.
espite this evolving trend, inflow iliac PTA/stenting
ombined with FFB does not ensure durable graft patency
n this presumptive high-risk patient population. These
ndings highlight the importance of careful inflow consid-
ration at the time of FFB, and its role as a significant
ontributor to overall FFB performance.
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Dr Kelley Hodgkiss-Harlow (Tampa, Fla). I would like to
congratulate Dr. Huded and colleagues for a very well-written
paper. Thank you for providing it to me well in advance of the
meeting.
After reading your paper, which examined the utilization
and impact of adjunctive endovascular intervention for femoral-
femoral bypass, I have several questions. First, given that you
mention several times that the gold standard for inflow disease
in the setting of leg ischemia is aortobifemoral bypass, did you
include any cohort of patients who underwent either aortobi-
femoral, aortoiliac, or iliofemoral bypass in your surgical results
to compare patency?
Second, as you mentioned, other papers have compared pa-
tency of iliac stenting in the setting of TASC classification of the
lesions stented. Do you have any information on those patients in
your cohort in terms of TASC classification of their iliac lesions?
Third, what was the mechanism of failure in your iliac stent
group (ie, did procedures fail secondary to iliac stent failure or
occlusion, or were they more related to femoral-femoral bypass
issues or outflow issues)?
Lastly, since your group advocates a thorough investigation of
the iliac arteries prior to proceeding with femoral-femoral bypass,
were you able to see if this was performed in your cohort either
through angiographic or pressure measurements or computed
tomography imaging?
Dr Chetan P. Huded. Thank you, Dr. Hodgkiss-Harlow, for
your commentary. In regards to your first question about compar-
ison to direct anatomic bypass, such as aortobifemoral bypass, we
did not include a group of patients who underwent aortobifemoral
bypass or other direct anatomic bypass. We would submit that theroup of patients in whom presumably aortobifemoral bypass
ould not be a suitable procedure.
In regards to your second question about TASC classification,
e did not include anatomic information about donor iliac lesions
n our patient cohort.Wewould agree that anatomic characteristics
f the donor iliac artery could affect outcomes in our cohort, and it
ould certainly be an interesting variable to investigate. Unfortu-
ately, our data is limited in that regard. Moreover, the decision to
reat donor iliac occlusive disease was determined by the discretion
f the attending surgeon at the time of surgery, and we remain
imited in our ability to discern differences at the surgeon level.
In regards to your third question about mechanism of failure
n our iliac stent group, we believe that the mechanism of failure in
hese patients is likely multifactorial. Conceivably, it could repre-
ent residual untreated inflow iliac occlusive disease despite iliac
tent placement. Additionally, regarding the question of outflow,
e found no significant difference among the three groups that
ould explain diminished patency in the iliac stent group. How-
ver, a specific mechanism of failure for each patient was not
ecorded, so failure in the iliac stent group cannot be definitively
ttributed to any specific mechanism.
In regards to your fourth question about investigation of
nflow status at the time of fem-fem bypass, we remain limited in
ur ability to draw conclusions about inflow investigation, given
hat the use of pressure gradients or other mechanisms of inflow
nvestigation was left to the discretion of the attending surgeon at
he time of surgery, and there was no standardized utilization of
ny of the mechanisms you discussed. These would certainly be
nteresting interventions to investigate in the future.
Dr Ravi Veeraswamy (Atlanta, Ga). I guess I’m looking for
ome guidance here. Would you or your group advocate that I not
ut iliac stents in before fem-fem bypasses? What is the take-home
essage here? It’s hard for me to understand how you’re getting
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When we walk out of this room, how should we change our
practice based on these data?
DrHuded. Thank you for your question. We certainly wouldur study supports the conclusion that thorough investigation of
onor iliac occlusive disease at the time of fem-fem bypass when
erformed in conjunction with endovascular intervention is criti-
al. Ensuring that donor iliac occlusive disease is adequately treatednot suggest that iliac stenting at the time of fem-fem bypass is
inherently at fault for diminished patency rates in these patients.
prior to placement of a fem-fem bypass is the strongest clinical
conclusion that can be drawn from our data.
